@article{eb535a0ce7014dfdb572d1136231ffc7,
title = "The AntiCD19 Antibody Drug Immunoconjugate Loncastuximab Achieves Responses in DLBCL Relapsing After AntiCD19 CAR-T Cell Therapy",
abstract = "Introduction: Chimeric antigen receptor T (CAR-T) cells targeting CD19 result in durable responses in approximately 40% of DLBCL patients. Loncastuximab tesirine, an antibody drug conjugate targeting CD19 with a pyrrolobenzodiazepine payload, has activity against DLBCL. Patients and Methods: We evaluated the outcomes of 13 DLBCL patients relapsed after CAR-T cells treated with loncastuximab in the LOTIS-2 trial. Results: Six patients (46%) had responses to loncastuximab (CR, n = 2). Median OS, PFS and duration of response after loncastuximab were 8.2, 1.4 and 8 months, respectively. Conclusion: Loncastuximab can achieve responses in patients progressing after CAR-T cells. Sequencing CD19-targeting therapies is possible in cases without CD19 loss.",
keywords = "CAR-T cell failures, Diffuse large B cell lymphoma",
author = "Caimi, {Paolo F.} and Ardeshna, {Kirit M.} and Erin Reid and Weiyun Ai and Matthew Lunning and Jasmine Zain and Melhem Solh and Kahl, {Brad S.} and Mehdi Hamadani",
note = "Funding Information: PFC reports research funding from ADC Therapeutics; grants Genentech. Consulting: ADC Therapeutics, Kite Pharmaceuticals, Verastem, Seattle Genetics, Amgen TG Therapeutics. Speaker's bureau: Celgene KMA reports research funding from ADC Therapeutics. Consulting from ADC Therapeutics, Celgene, Gilead, Takeda, Roche and Beigene. Support by the University College London (UCL)/UCL Hospitals (UCLH) Biomedical Research Unit. ER reports research funding from ADC Therapeutics. WA reports research support Nurix Therapeutics. Consulting: ADC Therapeutics, Nurix, Kymera. ML reports research funding from ADC Therapeutics, BMS, Curis. Consulting: Kite, Janssen, Karyopharm, Astra-Zeneca, Acrotech, BeiGene, Legend, ADC Therapeutics, Spectrum, Morphosys, Daiichi Sankyo, Myeloid Therapeutics, Kyowa Kirin. JMZ reports research funding from ADC Therapeutics. Consulting: Seattle Genetics, Kyowa Kirin, Verastem, Secura Bio, Legend Biotech, Ono Therapeutics. MS reports research funding from ADC Therapeutics, Partner therapeutics. Advisory Amgen, Seattle genetics. Speaker's Bureau: Amgen, Celgene. BSK reports research funding from ADC Therapeutics. Consulting: ADC Therapeutics. MH reports Research Support/Funding: Takeda Pharmaceutical Company; Astellas Pharma. Consulting/advisory board: Incyte Corporation; ADC Therapeutics; Celgene Corporation; Pharmacyclics, Magenta Therapeutics, Omeros, AbGenomics, Verastem, TeneoBio. Speaker's Bureau: Sanofi Genzyme, AstraZeneca, BeiGene. Funding Information: Additional support in data retrieval and analysis, as well as manuscript accuracy review by ADC Therapeutics Personnel, including Paul Thaler, Wendy Ma, and Yajuan Qin. Publisher Copyright: {\textcopyright} 2021 Elsevier Inc.",
year = "2022",
doi = "10.1016/j.clml.2021.11.005",
language = "English (US)",
journal = "Clinical Lymphoma, Myeloma and Leukemia",
issn = "2152-2669",
publisher = "Cancer Media Group",
}